
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings Corp shows a strong positive outlook driven by substantial growth in its whole exome and genome (WES/WGS) testing, with a remarkable 65% year-over-year increase in core revenue during the recent quarter. The company has strategically realigned its sales focus towards pediatric neurologists, which could further enhance its revenue trajectory, supported by an anticipated increase in average selling prices (ASPs) and gross margins (GMs). Notably, GeneDx raised its 2025 revenue guidance to $425-428 million, reflecting confidence in achieving a +39%-40% year-over-year growth, backed by the upward trend in testing volumes and ASPs.
Bears say
GeneDx Holdings Corp is projected to experience a substantial cash burn of ~$2 million per quarter this year, indicating a potential liquidity strain. The company's high denial rate of 45% as of Q3 2024, coupled with reliance on ongoing relationships with third-party payers for adequate reimbursement, presents a significant risk to its commercial success and future revenue generation. Additionally, the reduction in the sales force from 65 to 54 representatives reflects a strategic realignment aimed at cutting unprofitable accounts, yet it also highlights challenges in sustaining growth and market penetration.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares